Kailera Therapeutics, Inc. Common Stock (KLRA NASDAQ) stock market data APIs
$13.9846
1.25(8.9%)
as of September 11, 2026
Try our APIs with
free plan!
Kailera Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Prev. Close
13.9846
Open
15.2332
High
15.3645
Low
13.8744
52 wk Range
13.9-28.23
Market Cap
1 807 M
Shares Outstanding
130 M
EPS
-1.09
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kailera Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kailera Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Kailera Therapeutics, Inc. Common Stock Fundamental Data
Kailera Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -312 878 016
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Kailera Therapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -0.74
Get Kailera Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kailera Therapeutics, Inc. Common Stock News
New
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
Quick Read KLRA trades 29% below its IPO high but holds $1.17 billion in cash and carries a $42 analyst consensus price target. Merck's looming Keytruda revenue cliff and Novo Nordisk's need to defen...
2 Beaten-Down GLP-1 Stocks to Buy on the Dip
Key Points Novo Nordisk and Kailera Therapeutics have attractive GLP-1 pipelines. Both could cash in as demand for GLP-1 drugs soars over the medium term. 10 stocks we like better than Novo Nordisk �...
Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential
Kailera Therapeutics Inc. (NASDAQ:KLRA) is one of the best IPO stocks with huge upside potential. On July 7, Kailera Therapeutics announced positive topline results from two Phase 3 clinical trials co...
Update: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall
(Updates with the latest stock movement in the first paragraph and headline.) Kailera Therapeutic PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
Get Kailera Therapeutics, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
